tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Avidity Biosciences price target raised to $75 from $70 at Wells Fargo

Wells Fargo raised the firm’s price target on Avidity Biosciences (RNA) to $75 from $70 and keeps an Overweight rating on the shares. The firm highlights RNA’s first- and best-in-class position for all three of its muscle disease programs and notes the string of regulatory filings and decisions starting in year-end 2025, which should drive further momentum for the stock.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1